Effect of anticoagulation on hospitalization costs after intracranial hemorrhage in atrial fibrillation a registry study

Stroke

Volumn 47, Issue 4, 2016, Pages 979-985

  Vestergaard, Anne Sig ^a   Skjøth, Flemming ^b,c   Lip, Gregory Y H ^b,e   Larsen, Torben Bjerregaard ^b,d  

^a Faculty of Social Sciences   (Denmark)

^b AALBORG UNIVERSITY   (Denmark)

^c Unit of Clinical Biostatistics and Bioinformatics   (Denmark)

^d AALBORG UNIVERSITY HOSPITAL   (Denmark)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Anticoagulants; Atrial fibrillation; Cost and cost analysis; Hospitalization; Intracranial hemorrhages; Survival

Indexed keywords

WARFARIN; ANTICOAGULANT AGENT;

AGE; AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BRAIN HEMORRHAGE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HOSPITAL PATIENT; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL TIME; THROMBOEMBOLISM; CHEMICALLY INDUCED; COMPLICATION; ECONOMICS; HEALTH CARE COST; MIDDLE AGED; REGISTER; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; INTRACRANIAL HEMORRHAGES; MALE; MIDDLE AGED; REGISTRIES; RETROSPECTIVE STUDIES; WARFARIN;

EID: 84958811378     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.115.012338     Document Type: Article

References (25)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fbrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983-988.
2. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fbrillation: an update of the 2010 ESC guidelines for the management of atrial fbril-lation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33:2719-2747. doi: 10.1093/eurheartj/ehs253.
3. Hart RG, Diener HC, Yang S, Connolly SJ, Wallentin L, Reilly PA, et al. Intracranial hemorrhage in atrial fbrillation patients during anticoagula-tion with warfarin or dabigatran: the RE-LY trial. Stroke. 2012;43:1511-1517. doi: 10.1161/STROKEAHA.112.650614.
4. Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N, et al. The net clinical beneft of warfarin anticoagulation in atrial fbrillation. Ann Intern Med. 2009;151:297-305.
5. Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fbrillation: a systematic review. Am J Med. 2010;123:638-645.e4. doi: 10.1016/j.amjmed.2009.11.025.
6. Vest-Hansen B, Riis AH, Christiansen CF. Registration of acute medical hospital admissions in the Danish National Patient Registry: a validation study. Clin Epidemiol. 2013;5:129-133. doi: 10.2147/CLEP.S41905.
7. Schmidt M, Pedersen L, Sørensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol. 2014;29:541-549. doi: 10.1007/s10654-014-9930-3.
8. Kildemoes HW, Sørensen HT, Hallas J. The Danish National Prescription Registry. Scand J Public Health. 2011;39(7 suppl):38-41. doi: 10.1177/1403494810394717.
9. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refning clinical risk stratifcation for predicting stroke and thromboembolism in atrial fbrillation using a novel risk factor-based approach: the euro heart survey on atrial fbrillation. Chest. 2010;137:263-272. doi: 10.1378/chest.09-1584.
10. Brønnum Nielsen P, Larsen TB, Gorst-Rasmussen A, Skjøth F, Rasmussen LH, Lip GY. Intracranial hemorrhage and subsequent isch-emic stroke in patients with atrial fbrillation: a nationwide cohort study. Chest. 2015;147:1651-1658. doi: 10.1378/chest.14-2099.
11. PPP and exchange rates. Organisation for Economic Co-operation and Development (OECD.stat). http://stats.oecd.org/Index. aspx?datasetcode=SNA-TABLE4. Accessed May 28, 2015.
12. Welte R, Feenstra T, Jager H, Leidl R. A decision chart for assessing and improving the transferability of economic evaluation results between countries. Pharmacoeconomics. 2004;22:857-876.
13. Kristensen FB, Sigmund H. Metodehåndbog for Medicinsk Teknologivurdering. 2nd ed. København: Sundhedsstyrelsen, Enhed for Medicinsk Teknologivurdering; 2007.
14. Sundhedsdokumentation, Sektor for National Sundhedsdokumentation og Forskning. Takstsystem 2015-vejledning. Online: Statens Serum Institut; February 17, 2015. http://www.ssi.dk/~/media/Indhold/DK%20-%20dansk/Sundhedsdata%20og%20it/NSF/Sundhedsokonomi%20og%20fnansier-ing/Sundhedokonomi/Takster/Takster%202015/Takstvejledning2015.ashx.
15. Pedersen KM. Sundhedsøkonomi. 1st ed. København: Munksgaard; 2013.
16. InteraktivDRG. Statens Serum Institut. http://drgservice.ssi.dk/grouper. Accessed May 21, 2015.
17. Gregori D, Petrinco M, Bo S, Desideri A, Merletti F, Pagano E. Regression models for analyzing costs and their determinants in health care: an introductory review. Int J Qual Health Care. 2011;23:331-341. doi: 10.1093/intqhc/mzr010.
18. Jones AM, Rice N, D'Uva TB, Balia S. Applied Health Economics. 2nd ed. Oxon: Routledge; 2013.
19. Nielsen PB, Larsen TB, Skjøth F, Gorst-Rasmussen A, Rasmussen LH, Lip G Y. Restarting anticoagulant treatment after intracranial hemorrhage in patients with atrial fbrillation and the impact on recurrent stroke, mortality, and bleeding: a nationwide cohort study. Circulation. 2015;132:517-525. doi: 10.1161/CIRCULATIONAHA.115.015735.
20. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the effcacy and safety of new oral anticoagulants with warfarin in patients with atrial fbrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955-962. doi: 10.1016/S0140-6736(13)62343-0.
21. ATC/DDD index-B01AA Vitamin K antagonists. WHO Collaborating Center for Drug Statistics Methodology. http://www.whocc.no/atc-ddd- index/?code=B01AA03&showdescription=yes. Accessed May 21, 2015.
22. medicinpriser.dk (active substance: warfarin). Danish Medicines Agency. http://www.medicinpriser.dk. Accessed May 27, 2015.
23. Honorartabel 01-04-2015 DAGTID; §50 Grundydelser, §60 Laboratorieundersøgelser. Danish Medical Association. http://www.laeger. dk/portal/page/portal/LAEGERDK/Laegerdk/P-L-O/Overenskomster/Honorartabel/Honorartabel%201-4-15/Honorartabel%2001-04-2015%20-%20DAGTID. Accessed May 27, 2015.
24. Process and Methods Guides: Guide to the methods of technology appraisal 2013. Online: National Institute for Health and Clinical Excellence; April 2013. http://www.nice.org.uk/article/pmg9/resources/non-guidance-guide-to-the-methods-of-technology-appraisal-2013-pdf.
25. Jakobsen M, Fredslund EK, Kolodziejczyk C. Omkostninger ved blodprop i hjernen og blødninger blandt patienter med atriefimren i Danmark-en registerbaseret "cost of illness"-analyse. København K: Det Nationale Institut for Kommuners og Regioners Analyse og Forskning (KORA); 2014.